Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 15/20 | 0.50 |
| ▸ | PIK3CD | O00329 | 14/20 | 0.50 |
| ▸ | PIK3CB | P42338 | 9/20 | 0.50 |
| ▸ | PIK3CG | P48736 | 9/20 | 0.50 |
| ▸ | MTOR | P42345 | 9/20 | 0.50 |
| ▸ | RPTOR | Q8N122 | 1/20 | 0.48 |
| ▸ | MLST8 | Q9BVC4 | 1/20 | 0.48 |
| ▸ | PARP1 | P09874 | 6/20 | 0.47 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.47 |
| ▸ | PIK3C2A | O00443 | 1/20 | 0.46 |
| ▸ | PIK3C2B | O00750 | 1/20 | 0.46 |
| ▸ | STK10 | O94804 | 1/20 | 0.46 |
| ▸ | PAK4 | O96013 | 1/20 | 0.46 |
| ▸ | ABL1 | P00519 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
| ▸ | FGR | P09769 | 1/20 | 0.46 |
| ▸ | FER | P16591 | 1/20 | 0.46 |
| ▸ | PRKCA | P17252 | 1/20 | 0.46 |
| ▸ | JAK1 | P23458 | 1/20 | 0.46 |
| ▸ | TEC | P42680 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2674411 | 0.86 | PIK3CD (0.48) | PIK3CAPIK3CDPIK3CB | |
| SCHEMBL2674718 | 0.81 | PIK3CD (0.75) | PIK3CAPIK3CDPIK3CBPIK3CGMTOR | |
| SCHEMBL2673516 | 0.78 | PIK3CD (0.67) | PIK3CAPIK3CDPIK3CBPIK3CGMTOR | |
| SCHEMBL2675529 | 0.77 | PIK3CA (0.55) | PIK3CAPIK3CDPIK3CBPIK3CGMTOR | |
| SCHEMBL2674252 | 0.76 | PIK3CD (0.75) | PIK3CAPIK3CDPIK3CBPIK3CGMTOR | |
| SCHEMBL10276529 | 0.76 | PIK3CD (0.40) | PIK3CAPIK3CD | |
| SCHEMBL1181644 | 0.74 | PIK3CA (0.80) | PIK3CAPIK3CDPIK3CBPIK3CGMTOR | |
| SCHEMBL2465264 | 0.74 | PIK3CD (0.62) | PIK3CAPIK3CDPIK3CBPIK3CGMTOR | |
| SCHEMBL2112271 | 0.73 | PIK3CA (0.59) | PIK3CAPIK3CDPIK3CBPIK3CGMTOR | |
| SCHEMBL2675963 | 0.73 | PIK3CD (0.75) | PIK3CAPIK3CDPIK3CBPIK3CGMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8394796-B2 | Bicyclic pyrimidine PI3K inhibitor compounds selective for P110 delta, and methods of use | GENENTECH, INC. (US) | 2013-03-12 | — | — | US | disclosed |
| US-20120178736-A1 | BICYCLIC PYRIMIDINE PI3K INHIBITOR COMPOUNDS SELECTIVE FOR P110 DELTA, AND METHODS OF USE | CASTANEDO GEORGETTE (US) | 2012-07-12 | — | — | US | disclosed |
| US-8173650-B2 | Bicyclic pyrimidine PI3K inhibitor compounds selective for P110 delta, and methods of use | GENENTECH, INC. (US) | 2012-05-08 | — | — | US | disclosed |
| US-20100305096-A1 | BICYCLIC PYRIMIDINE PI3K INHIBITOR COMPOUNDS SELECTIVE FOR P110 DELTA, AND METHODS OF USE | GENENTECH, INC. | 2010-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178736-A1 | BICYCLIC PYRIMIDINE PI3K INHIBITOR COMPOUNDS SELECTIVE FOR P110 DELTA, AND METHODS OF USE | PIK3CA, PIK3R2, PIK3CD | PIK3CA 1/4885PIK3CD 3/4885PIK3CB 12/4885 |
| US-20100305096-A1 | BICYCLIC PYRIMIDINE PI3K INHIBITOR COMPOUNDS SELECTIVE FOR P110 DELTA, AND METHODS OF USE | PIK3CA, PIK3R2, PIK3CD | PIK3CA 1/4885PIK3CD 3/4885PIK3CB 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.